What You Should Know:
– Biotech and medical AI innovator Surge announced a $2.6M round co-led by HCVC, a global early-stage fund dedicated to high-potential technology startups, and Boutique Venture Partners, a leading fund based in the Silicon Valley . Veteran angel investors, including Nicolas Godin, the COO/CFO of Cardiologs, also participated in the round.
– Based on an exclusive license to Stanford’s patented postoperative complication prediction technology, Surge’s flagship product uses innovative machine learning algorithms to decode a patient’s immune system from a blood sample.
– With 30% of major surgeries currently resulting in complications and 40% of patients aged 65+ suffering long-lasting cognitive impacts after orthopedic or cardiac surgery, Surge’s solution enables physicians to quickly forecast the risk of postoperative complications and provide personalized interventions to reduce those risks.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Hitconsultant